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Summary: Hydrogen peroxide (H2O2) and methyl mercury induced the liberation of arachidonate and its
metabolites from human washed platelets. [14C]Eicosanoids were extracted from the supernatants of
[14C]arachidonate-prelabelled platelets and analysed by thin layer chromatography and radioscanning. Throm-
boxane B2 (TXB2), 12(S)-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and 12(S)-hydroxy-5,8,10,14-eicosa-
tetraenoic acid (12-HETE) were found s stabie metabolites, together with unreacted arachidonate. In the
presence of dazoxiben, a shift in eicosanoid metabolism was observed towards prostaglandin E2 (PGE2),
prostaglandin D2 (PGD2) and prostglandin F2a (PGF^), while in the presence of indomethacin there was a
shift towards 12-HETE and unmetabolized arachidonate. The concentration pattern of those metabolites
resembled that found with the physiological agonist, thrombin. H2O2 and methyl mercury also induced platelet
shape change, aggregation and secretion. The EC50 values for the induction of shape change and aggregation
were 27 and 850 μπιοΐ/ΐ for H2O2 and 0.33 and 2.7 μιηοΐ/ΐ for methyl mercury, respectively. The [3H]serotonin
release required higher Stimulus concentrations and amounted to 45% with 2 μηιοΐ/l H2O2 and to 16% with
3 μιηοΐ/ΐ methyl mercury. These effects on platelet function were absent in platelets exposed to acetylsalicylic
acid and prevented by indomethacin, the prostaglandin Ha (PGH2)/thromboxane A2 (TXA2) receptor antag-
onist, daltroban, and the functional antagonist, iloprost. In contrast, none of these drugs suppressed the
formation of (14C]eicosanoids, indicating that the platelet activation by H2O2 and methyl mercury essentially
requires previous PGH2/TXA2 formation. As expected, the thromboxane synthase inhibitor, dazoxiben, did
not prevent, but instead potentiated the activation by H2O2 and methyl mercury through accumulated PGH2.
These results show that H2O2 and methyl mercury selectively trigger the mobilization of endogenous arachi-
donate. In platelets exposed to acetylsalicylic acid or in the presence of a PGH2/TXA2 receptor antagonist,
they are model Stimuli for investigating endogenous eicosanoid formation without the interference of a
receptor^operated activation cascade. Therefore, H2O2 and methyl mercury are valuable tools for elucidating
the unresolved trigger meehanisms of eicosanoid release and for studying approaches to its selective Inhibition.
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 of platelet activation (3 — 5). Acetylsalicylic acid (as-
The synthesis f eicosanoids in human platelets is pirin®) and other non-steroidal anti-inflammatory
triggered by their physiological agoriists thrombin, drugs reduce platelet activation, because they inhibit
Collagen, ADP etc., but it is not essential for platelet —-.—
activation by these Stimuli (1). Eicosanoid release ') Abbreviations:
follows the Stimulation of phosphatidylinositol turn- ££EJ^ add;
Λ , . . t .- „ , j. 1 1 i HHT, 12(S)-hydroxy-5,8,10-heptadecatnenoic acid;
over and the nse in the intracelltilar diacylglycerol 12-HPETE, l2(S)-hydroperoxy-5,8,10,14-eicosatetraenoic
and Ca2"1" concentrations in stiiriulated platelets (2). acid;
PGHz1) and TXA^) are major but nstable -eicosa- JG» prostaglandin;
•j r j ·/> j f j * -A Tic» thromboxane;
noids formed from endogenous arachidonate, and
 EC^ concentration of an agonist that produces 50% eflect;
they play a functional role s strong feedback agonists TLC, thin layer chromatography.
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PGH2 and TXA2 formation from endogenous arach-
idonate released upon platelet Stimulation by either
of the above mentioned agonists. Antagonists acting
on the PGH2/TXA2 receptor exert a similar inhibitory
effect by preventing PGH2 and TXA2 from stimulat-
ing their common PGH2/TXA2 receptor (6). However,
neither cyclooxygenase inhibitors nor TXA2/PGH2
receptor antagonists suppress the mobilization of ar-
achidonate, which is the key event in eicosanoid for-
mation (7). Thus, these drugs cannot prevent the
mobilization and metabolism of free arachidonate to
biologically active products. In particular, cyclooxy-
genase inhibitors like acetylsalicylic acid may enhance
the formation of lipoxygenäse products, such äs 12-
HETE1) in platelets (8) and leukotrienes from platelet-
derived arachidonate in leukocytes (9). Therefore,
there is considerable pharmacological interest in the
search for inhibitors of the initiation of eicosanoid
release, namely the mobilization of arachidonate.
The biochemical link between the receptor-operated
activation cascade and eicosanoid release is still un-
known (10, l i), äs are specific inhibitors of the ar-
achidonate release (12). Several enzymes regulate the
free arachidonate concehtration. Phospholipase A2?)
supplies the major portion of free arachidonate by
liberation from phospatidylcholine and to a lesser
extent from phosphatidylethanolamine (13, 14). The
sequential action of phospholipase C2) and diglyceride
and monoglyceride lipases contributes to less than 15
percent of the arachidonate mobilized during platelet
Stimulation with thrombin (15). On the other hand,
arachidonyl-CoA synthetase2) (16) and lysophospho-
lipid acyltransferase2) (17) can rapidly Sequester a
large amount of free arachidonate· and reincorporate
it into the phospholipids by the reacylating pathway
(18). Therefore, the extent to which an activation of
the deacylation or an Inhibition of the reacylation
pathway contribute to the arachidonate mobilization
is the subject of an ongoing debate (19). The bio-
chemical study of arachidonate release is difficult,
because both membrane-bound enzymes and mem-
brane-associated Substrates are involved. Another
problem arises from the lack of specific biochemical
and pharmacological tools to interfere with the com-
plex mechanism that controls the concentration of
free arachidonate. Hydrogen peroxide (H2O2) and
2) Enzymes:
Arachidonyi-CoA synthetase (EC 6.2.1.15)
Prostaglandin synthase (Cyclooxygenase) (EC 1.14.99.1)
Lactate dehydrogenase (EC 1.1.1.27)
Lipoxygenase (1.13.11.12)
Lysophospholipid acyltransferase (EC 2.3.1.23)
Phospholipase A2 (EC 3.1.1.4)
Phospholipase C (EC 3.1.4.3)
Thromboxane synthase (EC 5.3.99.5)
methyl mercury chloride may prove to be such tools,
suitable for investigating the underlying mechanism.
It is shown in the present work that both agents
mobilize arachidonatCj independently of the activa-
tion cascade. Thus they act more directly on eicosa-
noid release than thrombin or other Stimuli, which
require the receptor-operated activation cascade.
• r
H2O2 belongs to the reactive oxygen species produced
by phagocytosing or otherwise stimulated neutrophils.
The amount produced by 2.5 · l O6 neutrophils reaches
6 nmol per 20 minutes (20, 21). A much less potent
source of H2O2 is the platelet stimulated with latex
particles or opsoriized zymosan (22). In studies on the
actions of H2O2 on platelets in vitro, different authors
report on the one hand an inhibition of platelet ag-
gregation induced by arachidonate (21, 23) and an
inactivation of the platelet cyclooxygenase (24); and
on the other hand, an enhancement by H2O2 öf the
effects of a variety of platelet agonists (25) and its
role äs a cosubstrate in the activation of the platelet
eyclooxygenäse2) (26). Our own work on the role of
reactive oxygen species in platelet physiology (27, 28)
led us to use H2O2 äs a model Stimulus of platelet
activation via thromboxane formation (29). While
H2O2 represents a physiological agent, methyl mer^
cury is formed by microorganisms from inorganic
mercury in industrial waste and accumulates in man
at the end of the food chain through its solubility in
lipids. It causes toxic effects on brain, liver and kid-
neys (for review see 1. c. (30)) but its mechanism of
action has not yet been clarified. Inhibitory effects of
methyl mercury were described ön adenylate cyclase
(31, 32) and on 12-lipoxygenase2) (33), leading to a
reduced inhibition of thromboxane synthesis by 12(S)-
hydroperoxy-5,8,10,14-eicosatetraenoic acid (l 2-
HPETE). Additionally, the whole blood glutathione
peroxidase activity and total blood glutathione is de-
creased by methyl mercury, whereas the serum levels
of TXB,1) and PGE^) increase (34). MacFarlane (23)
reported that methyl mercury indüces platelet shape
change, aggregation and the release reaction, and that
these effects could be suppressed by an inhibition of
the cyclooxygenase, The preserit stüdy demonstrates
that the target of H2O2 and methyl mercury is the
mobilization of endogenous arachidonate. Thus H2O2
and methyl mercury are üsefül model substances for
biochemical and pharmacological research on the in-
itial step of eicosanoid release.
Materials and Methods
Biochemicals
Perhydrol (= hydrogen peroxide) No. 7210 and methyl mercury
Chloride No. 806100 were purchased from Merck (Darmstadt,
F. R,. G.), thrombin from Behringwerke (Marburg, F. R. G.),
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indomethacin N o. 1-7378 and human albumin, essen tially fatty
acid free, No. A-3782 from Sigma GmbH (M nchen, F. R. G.)·
Dazoxibcn (UK 37248) was supplied by Pfizer Central Research
(Sandwich, UK), Sulotroban (BM 13.177) by Boehringer
Mannheim (Mannheim, F. R. G.), Iloprost (ZK 36374) by
Schering AG (Berlin, F. R. G.) and LU 41.453, an inhibitor of
the cyclic AMP phosphodiesterase, by Knoll AG (Ludwigs-
hafen, F. R. G.). [lJ4C]Arachidonic acid (2.0 TBq/mol) and
3H-labelled PGF*, PGE2, PGD2, TXB2 and 12-HETE s Stand-
ards for thin layer chromatography were obtained from New
England Nuclear (Dreieich, F. R. G.). [3H]Serotonin (5-hy-
droxy[G~3H]tryptamine creatinine sulphate) was obtained from
Amersham Buchler (Braunschweig, F. R. G.).
Preparation of washed platelets
Blood was taken only from healthy volunteers, who all dis-
claimed taking any drugs during the previous week. Disc shaped
washed platelets were prepared from whole blood anticoagu-
lated with 1/7 vol ACD NIH-formula A (8 g/l citric acid, 22
g/l sodium citrate, 24.5 g/l hydrous dextrose) according to our
method of washing with acid citrate (35). The platelets were
sedimented from platelet-rich plasma by 7 min centrifugation
at 330g and resuspended in a solution containing NaCl 120
mmol/1, KC1 5 mmol/1, CaCl2 2 mmol/1, MgCl2 l mmol/1, glu-
cose 5 mmol/1, albumin 2 g/l, apyrase 50 mg/1, sodium phos-
phate/NaOH 30 mmol/1, pH 6.5. When platelets were treated
with acetylsalicylic acid 5 mmol/1, a freshly prepared solution
of 20 mmol/1 in isotonic TES buffer pH 7.4 was added to the
platelet-rich plasma and incubated for 30 min at 22 °C prior to
the washing procedure. Where platelet secretion was to be
measured, platelet-rich plasma was incubated with 0.08 μηιοΐ/ΐ
(« 60 kBq) [3H]serotonin for 10 min at 22 °C in order to label
the secretory dense bodies. This procedure could be performed
separately or in combination with acetylsalicylic acid treatment.
• The washed platelets were finally suspended in a test medium
containing NaCl 120 mmol/1, KC1 5 mmol/1, CaCl2 l mmol/1,
MgCl2 0.1 mmol/1, glucose 5 mmol/1, albumin 0.5 g/l, apyrase
50 mg/1, sodium phosphate l mmol/1, TES/NaOH 30 mmol/1,
pH 7.4. The final platelet concentrations were 200 · 109/1 for
the measurements of platelet shape change, aggregation and
[3HJserotonin release and 2-1012/! for the measurement of
[14C]eicosanoid metabolism.
Rheooptical measurements of shape change and ag-
gregation
Shape change and aggregation were measured turbidimetrically
in a dual channel aggregoirieter (Labor, Ahrensburg, Ί?. R. G.)
at 37 °C by the method established by Born (36) with modifi-
cations s published earlier (35). Shape change experiments
were performed in the presence of EDTA 2 mmol/1 at a stirring
speed of 400 min"1. In aggregation experiments, 300 mg/1 of
fibrinogen were added and the stirring speed was 1000 min"1.
Preincubation of platelet suspensions with test substances
started 5 minutes prior to Stimulation. The instrumental ar-
rangement for measurements and the quantification of shape
change and aggregatipn were described previously (35).
Release of [3H]serotonin
The secretion of pH]sef otonin from platelet dense granules was
determined s the decrease of die platelet bound radioactivity
(35). The reuptake of serotonin was inhibited by the presence
of imipramine 2 μηιοΐ/ΐ. Aliquots were taken from incubates
three minutes after addition of the activating agent and were
mixed with 50 μΐ of an 0.1 mmol/1 ice-cold EDTA solution pH
7.4, rapidly cooled to 09C and centrifuged for 30s in an
Eppendorf 3200 centrifuge at 0 °C. The radioactivity of 200 μΐ
aliquots of the superaat nt was counted in a liquid scintillation
counter.
Platelet prelabelling with [ t 4C]arachidonate
For radiochemical assays, the washed platelets were prelabelled
with [14C]arachidonate. For this purpose platelets (200 · 109/0
were resuspended in a bufTer containing NaCl 120 mmol/1, KC1
5 mmol/1, MgCl2 l mmol/1, CaCl2 2 mmol/1, human albumin
2 g/l, glucose 5 mmol/1 and apyrase 50 mg/1 in phosphate-buffer
30 mmol/1, pH 6.5. p4C]Arachidonate was dissolved in the same
buffer by sonification for 2 minutes. The platelets were incu-
bated with [14C]arachidonate 3.25 μιηοΐ/ΐ for one hour at 37 °C.
Arachidonate was added in 10 portions at 6min intervals in
order to avoid platelet activation. Then the platelets were
washed twice to remove remaining free arachidonate and finally
resuspended in test buffer containing NaCl 120 mmol/1, KC1
5 mmol/1, MgCl2 0.2 mmol/1, CaCl21.2 mmol/1, human albumin
0.5 g/l (if not stated otherwise), glucose 5 mmol/1, phosphate
6 mmol/1, and apyrase 50 mg/1 in 0.1 mol/1 TES/HC1, pH 7.4.
The final platelet concentration was 2- 10I2/1.
Radiochemical assays
Samples of platelets (980 μΐ) prelabelled with [14C]arachidonate
were warmed to 37 °C for 5 minutes. Drug Solutions (10 μΐ)
were added and after another 5 minutes, platelet Stimuli were
applied in a volume of 10 μΐ. The final test volume was l ml.
In the controls, test medium was added instead of drugs. After
the desired time of incubation, the reaction was stopped by
acidifying to pH 3 with 10 μΐ of concentrated formid acid.
Samples were centrifuged at 10000g for 15 minutes and the
cell-free supernatants extracted twice with ethyl acetate. The
combined organic phases were dried under nitrogen, redissolved
in 100 μΐ of chloroform/methanol (2 + l, by vol.) and analysed
by thin layer chromatography. The overall recovery of the
radioactivity in the extracts and the platelet Sediments averaged
86 percent of the platelet-bound radioactivity after prelabelling.
Analysis of [14C]eicosanoids by radioTLC1)
Silica gel TLC-plates (No. 11798, Merck, Darmstadt, F. R. G.)
were heated to 110 °C for 15 minutes and subsequently allowed
to cool in a desiccator. After application, the plates were de-
veloped by a solvent System consisting of chloroform/methanol/
acetic acid/water (87+8+4+1, by vol.), which resolved well
the comigrating authentic Standards of 12-HETE, prostaglan-
dins and thromboxane B2 (fig. 1). The radioactive spots on the
TLC-plate were evaluated by a Berthold LB 2842 TLC-linear
analyser (Berthold, Wildbad, F. R. G.) with Integration Soft-
ware. After peak Integration and background subtraction the
percentage of radioactivity was calculated for each compound.
The liberation of radiolabelled eicosanoids was determined by
liquid scintillation counting of aliquots taken from the test
Suspension and cell-free supernatant. The extracts of the sedi-
ments were free of [I4C]eicosanoids.
Release of lactate dehydrogenase
As a parameter of cytoplasmic leakage, lactate dehydrogenase2)
was measured in an optical test (Monotest, Boehringer Mann-
heim, Mannheim, F. R. G.). Aliquots were taken from the in-
cubates five minutes after the addition of H2O2 or methyl
mercury, and the supern tants prepared by centrifugation for
30 s in an Eppendorf 3200 centrifuge at 0 °C. The lactate
dehydrogenase in the supernatants was compared with the total
lactate dehydrogenase released from control platelets after their
lysis by three cycles of freezing and thawing.
Statistics
Data are expressed s mean + S. E. M. Statistical coniparisons
were performed using Studenfs t-test for paired data. The null
hypothesis was rejected if p < 0.05. The concentration effect
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curves were calculated from data points by multiple iterations
using a non-linear sigmoidal leasl squares regression fit algo-
rithm developed by Marqitardt (37) and improved by Tabata &
Ito (38). The algorithm is part of the statistics and plotter
graphics Software package GRAPHPAD from ISI (USA).
Results
Treatment of [14C]arachidonate-prelabelled platelets
with hydrogen peroxide (H2O2) or methyl mercury
led to the release of radiplabelled metabolites and
unreacted arachidonate. The major [14C]eicosarioids
were ΊΧΆ2ι\ HHT1) and 12-HETE1) which appeared
in the same relative amounts and representing the
same percentage of the liberated [14C]eicosanoids, ir-
respective of whether the platelets were stimulated
with H2O2, methyl mercury or thrombin (fig. l and
tab. 1). With H2O2, a rise in the liberation of
[14C]eicosanoids continued up to 30 mmol/1, but be-
yond l mmol/1 H2O2 the amount of TXB2 and HHT
decreased in favour of unreacted arachidonate and
12-HETE (fig. 2). The optimal concentration of H2O2
for the Stimulation of TXB2 formation was approxi-
mately l mmol/1, which induced the liberation of 4.5
± 0.4% (n = 5) of the platelet-bound radioactivity
(fig. 2). With methyl mercury 20 μηιοΙ/1 and thrombin
l O3 IU/1, the liberation of [14C]eicosanoids amounted
to 5.6 ± 0.3% (n = 3) and 7.2 ± 0.5% (n = 3) of the
platelet-bound radioactivity, respectively. Inhibitors
of the cyclooxygenase, such s acetylsalicylic acid or
indomethacin (tab. 1), suppressed the TXB2 and HHT
formation and increased the formation of the 12-
lipoxygen se product, 12-HETE, but did not inhibit
the [14C]eicosanoid release (5.6 ± 0.3% vs. 4.9
± 0.5%, p > 0.1 for methyl mercury and 4.4 ± 0.4%
vs. 4.1 ± 0.3%, p > 0.1 for H2O2). The thromboxane
synthase2) inhibitor, dazoxiben, shifted the
[14C]eicosanoid metabolism from TXB2 and HHT to
the stable prostaglandins, PGE2J), PGD^) and
PGF^1) (tab. 1), which are spontaneously formed
from the labile prostaglandin, endoperoxide PGH2 (2,
39, 40). Iloprost and LU 41.453, which are functional
antagonists' in platelets, prevented the thrombin-in-
duced [14C]eicosanoid release, but had no effect on
the [14C]eicosanoid formation triggered by methyl
mercury (tab. 2).
H2O2 and methyl mercury caused platelet activation
s indicated by shape change, aggregation and
[3H]serotonin release. The concentration-effect rela-
tionships of the shape change and the aggregation are
shown on figure 3a and b. The [3H]serotonin release
required the highest Stimulus concentrations and it
amounted to approximately 45% with 2 mmol/1 H2O2
(fig. 4a) and 16% with 3 μηιοΐ/l methyl mercury (fig.
4b) in platelets aggregating in the presence of fibri-
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Fig. 1. Thin layer radiochromatograms of [14C]eieosanoids in
supernatants from human platelets prelabelled with
[14C]arachidonate and stimulated for l minute with (a)
methyl mercury 20 μπιοΙ/1, .(b) hydrogen peroxide l
mmoi/1, (c) thrombin l O3 IU/1 and (d) with methyl
mercury 20 μηιοΐ/ΐ in the presence of dazoxiben 10
μιηοΐ/l.
TXB2 == thromboxane B2
HHT = 12(S)-hydroxy-5,8,10-heptadecatrienoic
acid
12-HETE = 12(S)-hydroxy-5,8,10,14-eicosatetraenoic
acid
AA = arachidpnic acid
ΡΟΡτα = prostaglandin F2a
PGE2 = prostaglandin E2
PGD2 = prostaglandin D2
nogen. If aggregation was prevented by EDTA
2 mmol/1, [3H]serotonin release decreased to 20% and
3% (fig. 4a and 4b), respectively, whereas a f ll shape
change remained unaffected. H2O2 was used at con-
centrations not higher than 2 mmol/1 in functional
tests, since at higher concentrations it released small
bubbles of molec lar xygen that severely inteffefed
with the turbidimetric measurements of shape change
and aggregation. The aggregating effect of methyl
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Tab. 1. Effects of hydrogen peroxide, methyl mercury and thrombin on the formation of [14C]metabolites in platelets prelabelled
with [14C]arachidonate. The platelets were stimulated for l minute in the absence (= control) or the presence of dazoxiben,
daltroban or indornethacin. Platelet concentration: 200 · l O9/!·
12-HETE = 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid
HHT = 12(S)-hydroxy-5,8,10-heptadecatrienoic acid
[14C]Eicosanoids (percent
Prosta-
glandin
F*
Thromb-
oxane
B2
of total eicosanoids released)
Prosta-
glandin
E2
Prosta-
glandin
D2
HHT 12-HETE Arachi-
donic
acid
Hydrogen peroxide 1 mmol/1
Control
Dazoxiben 50
Indomethacin
μηιοΐ/ΐ
50 μηιοΐ/ΐ
0
0.9 + 0.3
0
31.1 + 3.3
0
0
0
22.7 + 4.6
0
0
3.6 + 1.0
0
18.4 + 0.6
0
0
22.7 + 2.1
36.8 ± 2.5
66.4 ± 6.8
27.9
36.0
33.7
±2.5
±4.7
±4.9
(n
(n
(n
= 5)
= 3)
= 3)
Methyl mercury 20 μηιοΐ/ΐ
Control
Dazoxiben 50
Indomethacin
Daltroban 20
Thrombin 103
Control
Dazoxiben 50
Indomethacin
μπιοΐ/l
50 μηιοΐ/l
μπιοΐ/l
IU/1
μπιοΐ/ΐ
50 μηιοΐ/ΐ
0
5.4 ± 2.1
0
0
0
2.5 + 0.3
0
38.3 ± 3.5
1.4 ± 0.8
0
40.6 ± 5.6
26.4 -l· 3.3
0
0
3.0 ± 1.1
42.3 + 2.5
0
4.0 ± 1.5
1.8 ± 0.4
33.5 + 6.4
0
0
10.0 H- 1.1
0
0
0
10.9 ± 1.8
0
22.5 ± 2.1
0
0
28.7 ± 2.3
27.5 + 3.5
0
0
29.5 ± 2.4
34.2 ± 1.6
61.1 + 8.4
18.7 ± 5.9
22.2 ± 3.0
28.9 + 4.5
73.3 + 2.7
6.8
6.8
39.0
8.0
22.2
24.3
26.4
±1.6
±1.3
± 5.6
± 2.0
±3.2
±1.0
+ 2.8
(n
(n
(n
(n
(n
(n
(n
= 6)
= 4)
= 3)
= 3)
= 3)
= 3)
= 3)
.?
1 10
[mmpl/U
100
Fig. 2. Effect of hydrpgen peroxide (0.5 — 30 mmol/1) on the
liberation of [I4C]eicpsanoids from platelets prelabelled
with [14C]arachidonate. The incubation time was l min-
ute. The formation of [14]eicosanoids is given s fraction
of the platelet-bound radioactivity. Inset: Formation of
[14C]TXB2 and [J4C]12-HETE s fraction of the total
[14C]eicosanoids released. n = 3.
TXB2 = thromboxane B2
12-HETE = 12(S)-hydroxy-5,8,10,14*eicosatetraenic
acid.
Tab. 2. Effect of iloprost and LU 41.453 on the [14C]eicosanoid
release induced by methyl mercury and thrombin. The
[14C]arachidonate-prelabelled platelets were stimulated
. for 2 min. Liber ted radioactivity "is given s the per-
centage of the platelet-bound radioactivity.
Release of [14C]eicosanoids (%)
Control
Iloprost 50 nmol/1
LU41.453 1 μπιοΐ/ΐ
Methyl mercury
20 μιηοΐ/ΐ
(n = 3)
5.3 ± 0.5
4.6 ± 0.3
n. s.
Thrombin
120 IU/1
(n = 3)
4.0 ± 0.3
0.21 ± Ol.03
p < 0.01
mercury strongly depended on the platelet concentra-
tion. Equipotent concentrations were 3 μηιοΐ/ΐ with
200 -109/1 and 20 μιηοΐ/ΐ with 2 · 1012/1 platelets, s
used in the experiments on platelet function and me-
tabolism, respectively.
In the presence of indornethacin and in platelets pre-
treated with acetylsalicylic acid, both H2O2
(< 2 mmol/1) and methyl mercury (< 3 μιηοΐ/ΐ) pro-
duced neither shape change nor aggregation and
[?H]serotonin release (tab. 3), whereas they still lib-
erated eicosanoids (tab. 1). The same results were
obtained with the TXA2/PGH2-receptor antagonist,
sulotroban, and the functional antagonists, iloprost
plus LU 41.453 (tab. 2 and 3). In contrast, the throm-
boxane synthase inhibitor, dazoxiben, augmented the
platelet responses to H2O2 and methyl mercury
(tab. 3).
In order to detect a cytolytic effect of H2O2 and methyl
mercury, lactate dehydrogenase was measured in the
platelet s pernatants after 5 min incubation of 200
• 109/1 or 2 · 1012/1 platelets with various concentrations
of those agents. Even with the highest concentrations
tested (30 mmol/1 for H2O2 and 0.1 mmol/1 for methyl
mercury), free lactate dehydrogenase did not exceed
3% with H2O2 and 4% with methyl mercury of the
total platelet lactate dehydrogenase activity. In con-
trol experiments neither H2O2 (l and 10 mmol/1) nor
methyl mercury (0.01 and 0.1 mmol/1) inhibited the
laotate dehydrogenase in the platelet lysate.
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Fig. 3. Concentration effect curves for the shape change
(Δ — Δ ) and the aggregation (o —o) induced by (a)
hydrogen peroxide and (b) methyl mercury (methyl-Hg).
The Symbols represent the means of 3—4 experiments
in 3 independent experimental series. A sigmoidal, three
parameter logistic function was calculated from the data
by multiple iterations with a Computer program. The
bottom value was set constant to 0, and the top value,
log(EC50) and the slope were estimated after multiple
iterations. The original values for the effects were then
normalized by means of the estimated top value
(= 1.00).
Fig. 4. Effects of indomethacin, daltroban and EDTA on plate-
let shape change, aggregation and [3H]serotonm release
induced by (a) hydrogen peroxide and (b) methyl mer-
eury (methyHig). The platelet-suspending medium con-
tained fibrinogen 300 mg/1.
a: Platelet activation induced by H2O2 (2 mrnol/1);
left side: contr l;
middle: indomethacin prevents any platelet response;
right side: EDTA suppresses aggregation and reduces
[3H]serotonin release, while a f ll shape change remains
unaffected.
b: Platelet activation induced by methyl mercury (20
μηιοΙ/1);
left side: contr l;
middle: the thromboxane receptor antagonist daltroban
prevents any platelet response;
right side: EDTA abolishes aggregation and diminishes
[3H]serotonin release without affecting the shape
change. The numbers at the erids of the curves indicate
the percentage of [3H]serotonin felease.
Tab. 3. Effect of indomethacin, dazoxiben and solutroban on shape change, aggregation and [3H]serotonin release induced by
various concentrations of H2O2 and methyl mercury (methyl-Hg). [3H]Serotonin release was determined upon Stimulation
in the presence of EDTA 2 mmol/1 to void aggregation. n = 5.
Contr l
Indomethacin 20 μηιοΐ/ΐ
Dazoxiben 20 μπιο1/1
Sulotroban 20 μτηοΐ/ΐ
Shape change
H202
500 μηιοΐ/ΐ
69.6 + 3.3
0
99.7 + 0.6
0
(%) Aggregation (%)
Methyl-Hg
0.5 umol/1
69.5 + 9.2
0
97.0 + 4.8
0
H202
1 mmol/1
68.3 4r 1.0
0
79.9 + 4.1
0
Methyl-Hg
5 μπϊοΐ/ΐ
63.6 + 2.3
0
79.8 + 5.6
0
[3H]Serotonin
release (%)
H202
2 mmpl/1
22.1
< 1
56.5
< 1
±1.6
±3.2
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Discussion
H2O2 and methyl mercury share with thrombin the
ability to induce a platelet activation accompanied by
the Formation of the platelet-derived eicosanoids ar-
achidonate, TXB2, HHT and 12-HETE. They appear
in the saine concentration ratios with either Stimulus,
showing that the metabolism of free arachidonate
follows its normal routes via 12-lipoxygenase2) to 12-
HETE and via cyclooxygenase2) and thromboxane
synthase2) to PGH2 and TXA2; the stable but inactive
TXB2 and HHT arise from the latter two compounds
(41, 42). The unstable intermediary products, PGH2
and TXA2, cause shape change, aggregation and se-
cretion, which can be suppressed by inhibitors of their
formation such s acetylsalicylic acid and indometh-
acin, or by inhibitors of their action such s the PGH2/
TXA2 receptor antagonists, sulotroban (43) and dal-
troban (44). The thromboxane synthase inhibitor, da-
zoxiben, enhances the platelet response (29) due to
accumulated PGH2, which shares the same receptor
s TXA2 (45). Acetylsalicylic acid (46) or daltroban
reduce but never suppress the platelet responses to
thrombin, ADP, platelet activating factor, serotonin
or the stable thromboxane mimetic U 46619 (1). In
contrast, acetylsalicylic acid, sulotroban and daltro-
ban prevented the platelet Stimulation by H2O2 and
methyl mercury. Therefore, platelet Stimulation by
H2O2 and methyl mercury essentially requires the for-
mation and action of PGH2 and TXA2, whereas each
of the other mentioned agonists also elicits a platelet
response independently of PGH2 and TXA2 forma-
tion. This implicates different mechanisms for trig-
gering eicosanoid forin tion with H2O2 or methyl
mercury and with the other physiolpgical agonists.
Thrombin, ADP, platelet activating factor, serotonin
and U 46619 act on platelets via specific receptors.
Their platelet-activating signal is transmitted by an
activation of the ph spholipase C and the formation
of inositol-l,4,5-trisphosphate and diacylglycerol,
which increase the intracellular free Ca2+ concentra-
tion and ctivate protein kinase C, respectively (47,
48). These events lead to shape ch ge, aggregation
and secretion and can be juahibited by agents that
stimulate the cyclic AMP formation, such s prosta-
cyclin (49, 50), Therefpre, agents capable of stimulat-
ing cAMP accumulation can be expected to inhibit
the thrombin-induced eicosanoid release, if this re-
lease depends on the thrombin-induced activation cas-
cade. In fact, the stable pr stacyclin mimetic, iloprost
(51), and the cyclic AMP phosphodiesterase inhibitor,
LU 41.453, inhibited the thrombin-induced eicosa-
noid release, but did not reduce the mobilization of
arachidonate and the formation of eicosanoids caused
by methyl mercury. This confirms that eicosanoid
release is secondary to platelet activation by throm-
bin, whereas methyl mercury does not require the
activation cascade for its effect on eicosanoid release.
The primary effect of H2O2 and methyl mercury on
arachidonate mobilization is also demonstrated by
the observation that indomethacin does not suppress
the eicosanoid release, although it prevents the H2O2-
and methyl mercury-induced shape change, aggrega-
tion and serotonin secretion.
A potent Stimulus for eicosanoid release in platelets
is an intimate platelet contact (5), an effect which is
most pronounced in citrated plasma (52). Therefore,
if platelets are allowed to aggregate, their aggregation
and secretion response is enhanced s a consequence
of PGH2/TXA2 fonnation. The aggregation (= con-
tact) can be definitely suppressed by EDTA, which
interferes with the binding of the aggregation cofactor,
fibrinogen, to its glycoprotein Ilb/IIIa receptors on
the platelet surface (53). Even in the presence of
EDTA, H2O2 2 mmol/1 and methyl mercury 3 μιηοΐ/ΐ
induced a f ll shape change and a certain release of
serotonin. Thus, these agents were potent Stimuli of
PGH2/TXA2 formation, even in the absence of an
aggregation-induced secondary mobilization of arach-
idonate.
Higher concentrations than 2 mmol/1 of H2O2 and
3 μπιοΐ/ΐ of methyl mercury were not used for specific
stimulations of the eicosanoid release, because of cer-
tain side effects. H2O2 (5 — 30 mmol/1) still enhanced
the eicosanoid release and 12-HETE production, but
suppressed the fonnation of TXB2 and HHT. This is
consistent with the Inhibition of the cyclooxygenase
observed by Kawaguchi et al. (24) in rabbit platelets.
In addition, oxygen bubbles were formed when H2O2
was present at > 1.5 mmol/1, due to the instability of
H2O2 at high concentrations. When more than 3 or
20 μηιοΐ/ΐ of methyl mercury were applied to 200
• 109/1 or 2 · 1012/1 platelets, respectively, shape change
and aggregation occurred, despite the presence of
indomethacin. In other words, methyl mercury at
these high concentrations elicits another platelet-ac-
tivating effect that is not mediated by the formation
and action of PGH2 and TXA2. Even at the highest
concentrations tested, lactate dehydrogenase libera-
tion remained below 3% with 30 mmol/1 H2O2 and
4% with l mmol/1 methyl mercury, showing that cell
lysis did not occur to an appreciable degree.
The mechanism whereby H2O2 and methyl mercury
selectively trigger the release of arachidonate remains
to be elucidated. In platelets, free arachidonate is
liberated mainly by ph spholipase A2 activated by
cytoplasrnic Ca2+, which increases during platelet ac-
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tivation (54). This mechanism is thought to be oper-
ative in the thrombin-induced eicosanoid release (55,
56) but is unlikely to be involved in the eicosanoid
release induced by H2O2 or methyl mercury. A small
rise in cytoplasmic Ca2+ is sensitively reflected by a
spherization of the platelets (57). In platelets exposed
to acetylsalicylic acid however, no shape change is
observed upon Stimulation with H2O2 or methyl mer-
cury, despite considerable arachidonate release.
Whether H2O2 or methyl mercury exert a direct, Ca2+-
independent effect on the phospholipase A22) activity
or interfere with the reacylating pathway of arachi-
donate is currently under investigation in our labo-
ratory. Both the phospholipase A2 (58) and the reac-
'ylating enzymes, arachidonyl-CoA synthetase2) (16)
and lysophospholipid acyltransferase2) (17), have high
activities in platelet membranes, which suggests a high
turnover rate of arachidonate deacylation and reac-
ylation. Under these conditions, an Inhibition of the
reacylating enzymes could just äs well lead to a rise
in free arachidonate, äs to an activation of the phos-
pholipase A2.. Since in contrast to thrombin and other
physiological agonists, H2O2 and methyl mercury
have a direct effect on arachidonate release, these
agents are valuable tools for investigating the bio-
chemical mechanism of arachidonate mobilization.
Irrespective of whether their target(s) is (are) located
within the phospholipase A2 or the reacylation path-
way, they provide models which not only pennit the
study of the regulation of free afdchidonate in plate-
lets, but also provide an experimental approach to its
specific Inhibition. Specific drugs that suppresss ar-
achidonate mobilization by an inhibitory effect on
phospholipase A2 or a stimulating effect on the reac-
ylating enzymes are not yet available. The use of
specific Stimuli of arachidonate release, such äs H2O2
and methyl mereury, should facilitate the search for
and the characterization of selective inhibitors of ar-
achidonate release.
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